Tebano G, Geneve C, Tanaka S, Grall N, Atchade E, Augustin P, Thabut G, Castier Y, Montravers P, Desmard M
Département d'Anesthésie Réanimation, Université Paris Diderot Sorbonne Cite, APHP, CHU Bichat-Claude Bernard, Paris, France.
Service de Réanimation, Centre Hospitalier Victor Dupouy, Argenteuil, France.
Transpl Infect Dis. 2016 Feb;18(1):22-30. doi: 10.1111/tid.12471. Epub 2016 Jan 30.
Multidrug-resistant (MDR) bacteria are a growing concern worldwide. The aim of this study was to describe the epidemiology and risk factors of MDR bacteria detected in respiratory invasive samples during hospitalization in the intensive care unit (ICU) after lung transplantation (LT).
This study was based on a retrospective analysis of 176 patients hospitalized in the ICU after LT in 2006-2012. Respiratory invasive samples were performed according to a routine protocol. MDR pathogens were defined according to in vitro susceptibility tests.
A total of 1176 bacteria were cultured. Susceptibility testing was performed on 1046 strains and 404 (39%) MDR were detected in 90 (51%) patients. Pseudomonas aeruginosa, coagulase-negative staphylococci, and Enterobacteriaceae (mainly Enterobacter species) were the most common MDR pathogens. On multivariate analysis, an ICU stay >14 days, presence of a tracheostomy, and previous exposure to broad-spectrum antibiotics were associated with MDR acquisition (odds ratio [OR] 3.7; 95% confidence interval [1.69-8.12]; OR 3.28 [1.05-10.28]; and OR 2.25 [1.17-4.34], respectively). We consistently observed an increasing emergence of resistance to several antibiotics, from week 1 to week 4 of ICU hospitalization: for ticarcillin, piperacillin-tazobactam, ceftazidime, imipenem/cilastatin, amikacin, and ciprofloxacin in P. aeruginosa; and for piperacillin-tazobactam, cefepime, and amikacin in Enterobacteriaceae.
A large proportion of MDR bacteria are detected on respiratory invasive samples in LT patients, and the risk of their emergence is mainly determined by the previous exposure to broad-spectrum antibiotics and the length of ICU stay. Adequate treatment requires broad-spectrum empiric antibiotic therapy.
耐多药(MDR)细菌在全球范围内日益引起关注。本研究的目的是描述肺移植(LT)后入住重症监护病房(ICU)期间在呼吸道侵入性样本中检测到的MDR细菌的流行病学及危险因素。
本研究基于对2006年至2012年LT后入住ICU的176例患者的回顾性分析。根据常规方案进行呼吸道侵入性样本检测。耐多药病原体根据体外药敏试验定义。
共培养出1176株细菌。对1046株菌株进行了药敏试验,在90例(51%)患者中检测到404株(39%)耐多药菌。铜绿假单胞菌、凝固酶阴性葡萄球菌和肠杆菌科细菌(主要是肠杆菌属)是最常见的耐多药病原体。多因素分析显示,入住ICU超过14天、气管切开术的存在以及既往接触过广谱抗生素与获得耐多药菌相关(比值比[OR]分别为3.7;95%置信区间[1.69 - 8.12];OR 3.28[1.05 - 10.28];以及OR 2.25[1.17 - 4.34])。我们持续观察到从入住ICU第1周到第4周,对几种抗生素的耐药性不断增加:铜绿假单胞菌对替卡西林、哌拉西林 - 他唑巴坦、头孢他啶、亚胺培南/西司他丁、阿米卡星和环丙沙星耐药;肠杆菌科细菌对哌拉西林 - 他唑巴坦、头孢吡肟和阿米卡星耐药。
LT患者的呼吸道侵入性样本中检测到很大比例的耐多药细菌,其出现的风险主要由既往接触广谱抗生素和入住ICU的时间长短决定。充分的治疗需要广谱经验性抗生素治疗。